TXMD · TherapeuticsMD Inc
United States · RS rating 39 · As of 2026-11-03
| Price | 1.78 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 39 / 33 / 39 / 85 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 27 / 23 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +13.9% |
| Distance from 52-week high | +35.7% |
| Market cap (USD) | $25.2M |